US Capitol Capsule: Will sequestration be a better outcome for biopharma?
This article was originally published in Scrip
Executive Summary
When the 12-member congressional "super" committee officially declared failure on 21 November – with the blame game starting well before the white flag was raised, and the mud-flinging likely to persist throughout the next year and perhaps beyond – biopharma may have dodged a bullet.